Home > Insider Trading > Filing (0001661181-21-000062)

Filing Details

Accession Number:: 0001661181-21-000062
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-07-20 20:45:00
Reporting Period:: 2021-07-16

Accepted Time:: 2021-07-20 20:45:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661181	Organogenesis Holdings Inc.	ORGO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1757373	S. Gary Gillheeney	C/O Organogenesis Holdings Inc. 85 Dan Road Canton MA 02021	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2021-07-16	24,313	$0.99	156,230	No	4	M	Direct
Class A Common Stock	Acquisiton	2021-07-16	115,450	$4.04	271,680	No	4	M	Direct
Class A Common Stock	Disposition	2021-07-16	110,329	$14.58	161,351	No	4	S	Direct
Class A Common Stock	Disposition	2021-07-16	29,434	$15.33	131,917	No	4	S	Direct
Class A Common Stock	Acquisiton	2021-07-19	160,237	$0.99	292,154	No	4	M	Direct
Class A Common Stock	Disposition	2021-07-19	160,237	$14.02	131,917	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-16	24,313	$0.00	24,313	$0.99
Class A Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-16	115,450	$0.00	115,450	$4.04
Class A Common Stock	Stock Option (Right to Buy)	Disposition	2021-07-19	160,237	$0.00	160,237	$0.99

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
680,097	2023-07-25	No	4	M	Direct
465,392	2030-04-22	No	4	M	Direct
519,860	2023-07-25	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.27 to $14.99, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.61 to $14.38, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
100% of the shares subject to the option are fully vested and exercisable.
The option became and continues to become exercisable in equal annual installments over four years beginning April 1, 2020.